Wave Life Sciences Ltd. boasted a balance sheet of $150.3 million as of Dec. 31, funds the company said during its fourth-quarter earnings should get the firm into 2019. But as always in the field of drug development, a little extra padding never hurts, and Cambridge, Mass.-based Wave Life priced a $100 million public offering Wednesday as it gets ready to move its first three candidates into the clinic targeting CNS and neurological disorders.